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| INTRODUC TI ON
Type 2 diabetes mellitus (T2DM) and chronic obstructive pulmonary disease (COPD) are two common chronic diseases that occur frequently in the elderly, and the incidence of T2DM combined with COPD tends to increase year by year. 1 The mechanistic associations between T2DM and COPD are complicated, multifactorial, and not completely understood, but they can influence the therapeutic method. Patients with T2DM are at increased risk for COPD, and COPD patients also have a higher prevalence of T2DM. Increasing numbers of studies indicate that T2DM can worsen the development of COPD, increasing the odds of mortality. 2 Rather, it has also been demonstrated that COPD may be a crucial risk factor that leads to the progression of T2DM. 3 Thus, although COPD and T2DM represent different diseases, there might indeed be a pathophysiological connection that links these important chronic diseases. As the prevalence of T2DM combined with COPD is really higher than before, simple and effective predictors for assessing the development and progress of T2DM combined with COPD are needed.
Recently, it has been reported that T2DM and COPD are not merely metabolic disorder or obstructive lung disease, but are also related to inflammatory dysfunction. 4 While the systemic inflammatory pathway provides the universal relation between COPD and T2DM, the mechanisms by which the systemic component arises are unclear. Therefore, lacking effective clinical tools to predict the incidence of T2DM combined with COPD emphasizes the need for the development of novel biomarkers in T2DM combined with COPD.
High-mobility group box-1, as one of the damage-associated molecular patterns (DAMPs), is a late inflammatory mediator. By binding to pattern recognition receptors (PRRs), DAMPs can attract and activate immune cells, and their release may therefore contribute to the exacerbation of inflammation. Although increasing numbers of studies indicate that HMGB1 is associated with the pathogenesis of T2DM and COPD, 5 research has rarely provided direct evidence to further confirm the relationship between HMGB1 and T2DM combined with COPD. The current study is aimed to investigate the relationship of serum HMGB1 levers with glycolipid metabolism, insulin resistance (IR), and lung function, and whether HMGB1 can predict the incidence of T2DM combined with COPD. 6 and patients with COPD were in accordance with the definition and criteria of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines. 7 All specimens were obtained with patients' informed consent, and the study was approved by the hospital ethics committee of the Second Affiliated Hospital of Nanchang University.
| MATERIAL S AND ME THODS

| Subjects
| Inclusion and exclusion criteria
All participants meeting the following criteria: (a) signed the in- 
| Clinical and biochemical evaluations
General data of patients were collected through the hospital infor- 
| Statistical method
Statistical analyses were performed using SPSS 24.0 (SPSS Inc) for
Windows. Categorical data were described as number and percentage.
Distribution and homoscedasticity were verified by the Kolmogorov-Smirnov test and Levene's test, respectively. Comparisons of categorical data were done using the chi-square test. Normally distributed data were expressed as mean ± standard deviation (SD) and analyzed using independent-samples T tests for two groups and analysis of variance 
| RE SULTS
| The baseline characteristics and HMGB1 of all participants
There were no significant differences among the study subjects in variables including age, gender, disease duration, systolic pressure, and diastolic pressure. In comparison with the patients with T2DM and healthy control, patients with COPD and patients with T2DM combined with COPD had higher levels of smoking history (P < 0.01) as shown in Table 1 .
| Serum HMGB1 levels
In comparison with the healthy control, patients with T2DM, COPD, T2DM combined with COPD had significantly higher levels of HMGB1 (P < 0.01). Furthermore, patients with T2DM combined with COPD had a higher level of HMGB1 than patients with T2DM and patients with COPD (P < 0.05). There was no significant difference between the patients with T2DM and patients with COPD in the serum HMGB1 concentration as shown in Figure 1 
| Relationship between serum HMGB1 level and parameters of metabolism and lung function
The levels of serum HMGB1 were positively correlated with HbA1c, FPG, FINS, HOMA-IR, and smoking history and negatively correlated with HOMA-β, FEV1/FVC, and FEV1%pred as shown in Table 2 .
| Multiple regression analyzed risk factor for T2DM combining COPD
In patients with T2DM, after adjusting for gender, TG, LDL, HDL, and HbA1c, HMGB1 and age independently associated with T2DM combined with COPD as shown in Table 3 .
In patients with COPD, after adjusting for age, gender, smoking history, CRP, FEV1/FVC, and FIB, HMGB1 independently influenced the attainment of T2DM combined with COPD as shown in Table 4 . Smoking history(y) 0 (0,0) 37 (0,40)* 40 (0,50)* 0 (0,0)
TA B L E 1 Baseline characteristics and HMGB1 of participants
Note: Results are represented as n, mean ± SD or M (Q). Abbreviations: COPD, chronic obstructive pulmonary disease; n, number of subjects; T2DM combined with COPD, type 2 diabetes mellitus combined with chronic obstructive pulmonary disease; T2DM, type 2 diabetes mellitus. *Compared with T2DM and control P < 0.01. 
| D ISCUSS I ON
Type 2 diabetes mellitus (T2DM) is a long-term metabolic disorder that is characterized by high blood sugar, insulin resistance (IR), and relative lack of insulin due to pancreatic beta cells not functioning. 9
Chronic obstructive pulmonary disease (COPD) is a type of obstructive lung disease in which chronic, incompletely reversible airflow limitation and airway inflammation exist. 10 The incidence of T2DM combined with COPD is much higher than before. It has been estimated that approximately 10% of patients with T2DM will also have COPD. 11 Moreover, patients with COPD also have a higher prevalence of T2DM and it has been predicted that 18.7% of patients with COPD will also have T2DM, while that number in the general population is 10.5%. 12 To date, most pharmacological methods for the treatment of T2DM and COPD are only symptomatic and do not tackle the inherent cause of these symptoms. 3 The most relevant approach to simultaneously treat COPD and T2DM is likely to interfere with the essential inflammatory relation.
While increasing numbers of studies indicate that the systemic inflammatory pathway provides the general link between COPD and T2DM, 1 Additionally, it has been reported that molecular mechanism of increasing of hyperglycemia-induced HMGB1 expression may be related to insulin resistance (IR). 8 IR often leads to the occurrence of hyperinsulinemia, which is a common state of T2DM. In the current study, we observed that serum HMGB1 was positively correlated with FINS and HOMA-IR and negatively correlated with HOMA-β, indicating that HMGB1 may impair β-pancreatic cell function and it may increase IR, which were consistent with the opinion above.
Furthermore, in the current study, serum HMGB1 level was found to be positively correlated with the smoking history and negatively correlated with FEV1/FVC% and FEV1%pred. It was probably because cigarette smoking, the most well-known causative factor of COPD, induced neutrophils autophagy and necrosis by activating platelet-activating factor receptor (PAFR) and releasing neutrophil elastase. 18 Neutrophil elastase had a strong injury effect on lung parenchyma, and therefore, the lung function was severely damaged mainly reflected in the lower FEV1/FVC% and FEV1%pred.
Furthermore, the necrosis of neutrophil cells leads to HMGB1 release, which recruited other neutrophils in a self-maintaining process. This vicious circle promoted COPD progression. Therefore, inhibiting HMGB1 and its receptor RAGE and blocking cigarette smoking-induced neutrophils necrosis may be the targets for further researches. Moreover, it has been reported that lung function was associated with blood glucose concentrations. Normally, glucose does not appear in airway secretions. 19 Nevertheless, an increase in blood glucose concentrations might induce an increase in the glu- As a proinflammatory factor, HMGB1 was able to sustain microglial activation and injure hippocampal neurons by directly acting on those neurons. 22 The activation promoted positive feedback and aggravated neuronal damage further. In a cellular monoculture or coculture system, HMGB1 siRNA was able to alleviate the activation of microglial cells and the apoptosis of hippocampal neurons induced by high glucose and hypoxia. 23 It means that inhibition of HMGB1 may break the vicious cycle to alleviate neuroinflammation and hippocampal neuronal apoptosis and to prevent cognitive deficits.
Taken together, we found circulating HMGB1 concentrations were significantly increased in patients with T2DM and COPD TA B L E 4 Regression model assessing factors affecting the attainment of T2DM combined with COPD in patients with COPD especially in T2DM combined with COPD. Serum HMGB1 level was positively correlated with parameters of glycolipid metabolism, IR, body fat, and smoking history and negatively correlated with lung function. Furthermore, the increase of HMGB1 level in serum was independent risk factor for T2DM combined with COPD, providing useful information in predicting T2DM combined with COPD in T2DM or COPD patients. Therefore, HMGB1 may be involved in the pathology of T2DM and COPD and provide new ideas for the treatment of T2DM combined with COPD.
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